作为高通量合成和 DNA 测序的先驱者，Leproust 博士正在颠覆市场，以实现 DNA 应用的指数级增长，包括化学品/材料、诊断、治疗、食品和数字数据存储。2020 年，BIO 向她颁发了 Rosalind Franklin 领导奖。《外交政策》杂志将她评为 100 位全球领先思想家之一，而 Fast Company 则将她评为商界最具创造力的人物之一。加入 Twist Bioscience 之前，她曾在 Agilent Technologies 履任要职，期间曾设计出大获成功的 SureSelect 生产线，从而降低了测序成本，并阐明了数十种孟德尔疾病的机制。她还开发了寡核苷酸库合成技术，并启动和领导了团队的产品和业务拓展活动。Leproust 博士设计并开发了多个商业合成平台，用于简化微阵列芯片的生产制造过程。She serves on the Board of Directors of GeneDx and is a co-founder of Petri, an accelerator for start-ups at the forefront of engineering and biology. Leproust 博士发表过 30 多篇经过同行评议的论文，其中许多是关于合成 DNA 的应用，同时她还是多项专利的作者。她曾在休斯顿大学取得有机化学博士学位，并在里昂工业化学学院取得工业化学硕士学位。

Patrick 此前在生物试剂、B2B 和定制制造企业有着良好表现，成功实现了销售额的高速增长。他拥有相关的技术背景，并且能够识别出客户未被满足的需求，因此适合领导我们的商务工作。Paddy 在加入 Twist Bioscience 之前任职于 Enzymatics（近期被 QIAGEN 收购），担任销售与市场副总裁，负责领导北美和欧洲的商务活动；他在任职期间实现了显著的顶线增长，并将业务范围延伸到了商务客户。加入 Enzymatics 之前，Paddy 曾任多个商务要职，包括 Agilent Technologies 的业务开发总监、Beckman Coulter Molecular Diagnostics 的产品开发总监以及 Invitrogen and GE Healthcare/Amersham International 产品开发部门的多个技术职位。此外，Paddy 博士目前还任职于 Lasergen 的科学顾问委员会，并且之前曾任职于 Enzymatics 的科学顾问委员会。他拥有南安普敦大学的核酸化学博士学位和赫瑞瓦特大学荣誉商学士学位。

Thorburn 是一名经验丰富的技术高管，在私营和国营技术公司有 30 多年的财务和运营从业经验。在加入 Twist Bioscience 前，他曾担任 Televerde 首席销售官，后者是一家专注于在全球扩展业务的需求生成和销售促进的企业。在加入 Televerde 之前，他曾担任过数家私营和国营公司的临时首席财务官，包括 Enercore、Next Autoworks、Fisker Automotive 和 Numonyx（被 Micron 收购）。在担任 Numonyx 的临时首席财务官期间，他负责协调 ST Microelectronics 与 Intel Flash Memory 部门的合并，并协调融资事宜以支持这家营收 20 亿美元公司的运营。在加入 Numonyx 之前，他曾担任 ZiLOG 的董事长兼首席执行官，带领共同公司成功转型、成功上市以及成功出售给 IXYS。Jim 一直担任 Texas Pacific Group (TPG) 的运营顾问、ON Semiconductor 的首席运营官兼联席总裁，并领导了 ON 的收购和上市。

在加入 ON 之前，他曾在 National Semiconductor 的多个业务部门担任过多个财务高管职务。

Thorburn 先生曾任 IXYS Corporation 的董事会成员。他在格拉斯哥大学获得农业经济学的理学士学位（荣誉），并通过了英国皇家特许管理会计师公会考试。

Aaron 是一位经验丰富的生物学领导者，擅长团队管理，发现和开发新的一流抗体疗法。在加入 Twist Bioscience 之前，他曾担任 LakePharma 的首席科学官，领导加利福尼亚抗体中心，致力于为客户研发新的抗体疗法。在 LakePharma 之前，他曾相继担任 Sutro Biopharma, Inc. 的研究副总裁和 Surrozen 的蛋白质科学副总裁，监管所有研发职能部门。他还曾在 OncoMed Pharmaceuticals 担任抗体工程高级总监，负责人类抗体先导化合物的发现，并通过 IND 申请，担任过数个关键抗体项目的项目组组长。在加入 OncoMed 之前，Aaron 在 Dyax Corp.履任要职，最终担任先导化合物发现高级总监，采用公司专有的噬菌体展示技术领导抗体、肽和小型蛋白质的发现。他在麻省理工学院获得博士学位，学习了 MHC II 类结构功能关系。在抗体领域，他发表了 30 多篇同行评审论文，并申请了 40 项授权专利。

陈博士是一位战略思想家，他在识别、开发和发布 NGS、合成生物学和其他生命科学领域的创新产品方面有着丰富经验。Twist 成立后不久，他就加入了公司，主要负责合成生物学和 NGS 产品系列的开发。陈博士构思并实施了包含对 SARS-CoV-2 和其他传染病的合成控制在内的全新 NGS 产品线，开发了基因合成和 NGS 靶向富集生物化学、工作流、试剂盒和基础设施，并联合硬件、软件和硅等领域的工程师们共同构建了公司的原型 DNA 合成器，为 Twist 奠定了技术基础，实现了规模化生产。陈博士发表了众多经过同行评议的论文，并在寡核苷酸合成和合成寡核苷酸的应用领域拥有多项专利。他在威斯康星大学麦迪逊分校获得了化学博士学位，在中国北京大学获得了化学学士学位。

Paula Green 是一位经验丰富的人力资源执行官，他在开发和使用有关提升领导力、赋能高效组织的高影响力人员战略、解决方案、流程和工具方面有着骄人业绩。加入 Twist Bioscience 之前，她曾担任 QIAGEN 公司的人力资源副总裁，并在并购重组和其他重大的企业交易中负责带领 50 名人力资源专家，为 4,000 名员工提供支持。她曾是 Operon Technologies（被 QIAGEN 收购）的人力资源经理，主要负责制定战略、监督所有员工的福利以及提供培训、招聘和留用项目。她还曾担任旧金山联邦住房贷款银行的人力资源顾问。Paula 拥有旧金山大学的组织行为学学士学位。

Chet’s areas of expertise include cloud computing, application and solution architecture, cybersecurity, artificial intelligence and data analytics. Prior to joining Twist, Chet served as chief information officer at Wineshipping, where he successfully led the company’s transformation from logistics to a technology-driven organization, optimizing the technology stack, enhancing the consumer experience, and driving internal efficiency. Previously, he held key leadership positions including vice president and global head of IT at Intapp and chief information officer and head of technology at Magento Commerce (acquired by Adobe). He also held a series of progressively responsible roles at Applied Micro Circuits. Chet holds a master’s of applied science in engineering from the University of British Columbia and a bachelor’s in technology from the Indian Institute of Technology.

Mark is experienced in improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. Prior to joining Twist, Mark served as corporate senior vice president, operations, global supply chain at Excelitas Technologies Corporation where he established a global footprint, drove global supply chain optimization measures, enabled scale up and drove revenue growth. His responsibilities included global supply chain planning, global sourcing and procurement supply, internal supply, supply quality and logistics inbound and outbound movement of freight. Prior to Excelitas, Mark was director, global supply chain management and general manager of resale product operations at Bio-Rad, Inc., where he managed buy-sell products, which grew in revenue to $270 million, significantly improving profitability over his time in the role. He previously held leadership positions including vice president operations, global manufacturing, supply chain and logistics at Celerity Group; director, operations management at Solectron corporation; and senior supply chain operations manager at Apple Computer, Inc. Before joining industry, Mark served in the United States Marine Corps. He holds an MBA from National University and a B.S. in electrical and computer engineering from University of Illinois, Urbana-Champaign.

Bill 是一位经验丰富的企业家和硅工程专家。他曾是四家初创企业的创始人或首位员工，并为初创企业提供咨询。作为 Complete Genomics 的硬件工程副总裁，他主导建立了自己的测序技术，并交付了三代人类基因组芯片和测序仪。Bill 曾两次获得美国国防部高级研究计划局 (DARPA) 的数百万美元拨款，用于开发基于硅微机械加工的创新技术。Bill 的职业生涯横跨了研究、产品开发和半导体器件加工等领域。他拥有亚利桑那大学的光学科学博士学位和密歇根大学的电子科学硕士学位，并曾在劳伦斯利弗莫尔国家实验室担任物理学家。

Tracey joined Twist in December 2021 through the acquisition of Abveris, a company offering premium in vivo antibody drug discovery services, in November 2021. Prior to Twist, she served as CEO of Abveris. Tracey initially served as Abveris’ chief operating officer where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns. Before Abveris, she served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to traditionally difficult therapeutic targets, including leveraging the Adimab platform to generate antibodies against GPCRs. Previously she worked for a contract research organization specializing in in vivo antibody. She received her B.S. in Chemical and Biological Engineering from the Massachusetts Institute of Technology and her Executive MBA from Quantic School of Business and Technology.

Nimisha joined Twist in March 2014 and was instrumental in automating processes and procedures to fuel the growth of Twist into a leading global manufacturer of synthetic DNA. She built out the core technology team and scaled up key laboratory processes, workflows and automation, which enabled the high-throughput production of novel synthetic DNA-based offerings. Prior to joining Twist, Nimisha held key technical and leadership positions at various startups as well as academic and national laboratories where she drove the development and scale up of microfluidics technologies for multiplexed pathogen detection and in vitro diagnostics. She holds a B.S. in chemical engineering from the Indian Institute of Technology, New Delhi and an M.S. and Ph.D. in chemical engineering from the University of Michigan, Ann Arbor where she studied the intersection of genetics, miniaturization, and dynamics of complex fluids.

作为一名在生物制药行业拥有超过 25 年经验的高级传播主管，Angela 擅于清晰的表达和一致的传播，这让她在主要利益相关者中获得了一定的知名度，并承担了整个公司的文化和传播方面的工作。在加入 Twist 之前，她有 20 年的咨询服务经验，与生物制药、医疗设备和诊断领域的客户合作创建了关键信息，从而实现与外部受众的有效沟通。在开始咨询服务之前，Angela 曾担任 Exelixis 公司的投资者关系和企业传播部主管。她也在 Russell-Welsh 公司（一家精品医疗通信公司）工作了数年，期间与各种公共和私人客户就广泛的通信服务进行过合作。她拥有华盛顿大学的细胞和分子生物学理学学士学位和商业营销文学学士学位。她目前担任国家慈善联盟当地分会的临时副总裁。

Dennis Cho is a seasoned in-house business attorney with a proven track record of agile strategic guidance and practical problem solving. Prior to Twist, he served as assistant general counsel at CytomX Therapeutics, where he was department head for all deals and contracts as well as day-to-day lead on compliance and numerous other legal subject matters. Prior to CytomX, Mr. Cho was the lead transactional attorney on antibody-related licenses and collaborations, major commercial agreements, and combination trials at Seattle Genetics. Before that, he spent nine years at Celgene as the lead West Coast attorney supervising over 100 business transactions, including in- and out- licenses, options, collaborations and M&A agreements, and held primary legal responsibility for Celgene’s alliances, equity investments and “big data” machine learning initiative. Prior to Celgene, Mr. Cho served as general counsel for four private and public companies. He earned his J.D. and a B.A. in Molecular Cell Biology (Genetics) from University of California, Berkeley.